ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES10 MARCH 2025 at 19.00 EET Orion Corporation: Transfer of 191,911 own B shares on 10 March 2025 In accordance with a decision by the Board of Directors, Orion Corporation has on 10 March 2025 transferred altogether 191,911 Orion Corporation B shares held by the company as a share reward for earning period 2022–2024 and a reward for commitment part to the persons belonging to the Share-based Incentive Plan of Orion Group. The transfer is based on the authorisation by the Annual General Meeting of 23 March 2022. The price per share of the transferred shares is EUR 53.7158, which is the volume weighted average quotation of the Orion Corporation B share on 10 March 2025. Accordingly, the total transaction price of the transferred shares is EUR 10,308,652.89. After the share transfer, the total number of own B shares held by Orion Corporation is 440,944. Orion Corporation has informed about the Share-based Incentive Plan in stock exchange release on 10 February 2022. Orion Corporation Liisa HurmePresident and CEO Olli HuotariEVP, Corporate Functions Contact person:Olli Huotari, EVP, Corporate Functions tel. +358 10 426 3054 Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandwww.orionpharma.com Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion’s net sales in 2024 amounted to EUR 1,542 million and the company had about 3,700 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.